Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

According to real-world data, no survival advantage was seen when comparing 3 frontline CDK4/6 inhibitor combinations in ...

T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.

Morgan Stanley analyst Maxwell Skor has maintained their neutral stance on RPTX stock, giving a Hold rating yesterday.Pick the best stocks and ...

Northwest Bio is near 5-year lows with DCVax vaccine in review. Mixed opinions on trial, but potential remains. Cash issues ...

Using OncoCast-MPM, a ML tool developed at Memorial Sloan Kettering, they generated three models to predict progression-free survival (PFS) with CDK4/6 inhibitors: one based on clinicopathological ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.

The FDA issued a second, expanded recall of duloxetine after higher than acceptable levels of a cancer-causing chemical were ...

This drug approval followed the publication of the EMBARK trial, a randomized phase III trial of biochemically recurrent patients who had high-risk disease, defined by a PSA doubling time (PSADT) ≤9 ...

An experimental hormone therapy pill has shown promise in extending the lives of women with tough-to-treat advanced breast ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), retaining the price target of $12.00.Pick ...

Imlunestrant worked particularly well in combination with the targeted therapy drug Verzenio. The combo helped women with ...